Altasciences completes acquisition of US-based CRO WCCT Global

Mid-size CRO/CDMO Altasciences has acquired early-stage clinical research organisation (CRO) WCCT Global.

laboratory — The acquisition would complement Altasciences’ current clinical operations in Canada’s Montreal and Kansas City in US. Credit: Michal Jarmoluk from Pixabay.

Mid-size CRO/CDMO Altasciences has acquired early-stage clinical research organisation (CRO) WCCT Global.

Free Report

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.

by GlobalData

Enter your details here to receive your free Report.

By clicking the Download Free Report button, you accept the terms and conditions and acknowledge that your data will be used as described in the GlobalData privacy policy By downloading this Report, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

WCCT is located in southern California on the US West Coast.

Altasciences noted that the acquisition will complement its current clinical operations in Montreal, Canada, and Kansas City, US.

News

Inhibrx concludes Phase I dose escalation of solid tumour therapy

News

Cara Therapeutics reports positive Phase II notalgia paresthetica trial

Clinical Trials

Sanofi Phase III tolebrutinib trials placed on partial hold by US FDA

Clinical Trials

Ultimovacs Phase II melanoma trial concludes subject recruitment

WCCT’s facility lies within close access to Altasciences’ preclinical facility in the state of Washington.

Altasciences co-chief operating officer Steve Mason said: “This acquisition expands Altasciences’ footprint by providing Phase I and II clinical pharmacology services on the West Coast, and adds 180 beds to our current 400-bed offering.

“Furthermore, it allows us to enhance our capabilities with expertise in ethnobridging and other speciality areas for hard-to-recruit study populations.”

The acquisition was completed on 12 February.

Altasciences CEO Chris Perkin said: “This acquisition is an integral part of Altasciences’ strategic growth plan to provide a comprehensive, fully integrated early phase drug development solution to address the ever-changing outsourcing challenges of biopharmaceutical companies across the globe.”

Founded in 1998, WCCT Global has conducted more than 600 Phase I studies in its area of expertise, out of about 1,000 Phase I-IV studies the company has conducted so far.

WCCT Global executive chairman Gregory Hanson said: “Joining the Altasciences team will enhance our offering while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients.”